Visceral fat: what it is, how to measure it, and what lowers it

Reviewed 21 sourcesPublished by PepVault

Visceral fat explained: how it differs from belly fat, the waist cut-offs that flag it and what cut it in trials, from aerobic exercise and HIIT to tirzepatide.

Grey-haired man in a white linen shirt pulls a grey carry-on along a palm-lined seaside promenade
Last reviewed
Sources
21
Questions
8
Compounds
4

The short answer

Visceral fat is the fat packed around your organs inside the abdomen, and more of it is linked to higher heart disease and diabetes risk. A waist above 102 cm (40 in) for men or 88 cm (35 in) for women marks the risk. In trials, regular aerobic exercise or interval training lowered it even without weight loss, and tirzepatide cut it by 40% in 72 weeks.

Every number checked at its primary source · · 21 sources · How we research

Evidence: Randomized trials and meta-analyses of exercise and diet measured by CT or MRI; drug results from DEXA substudies of phase 3 trials, mostly exploratory and maker-funded; the health links come from observational cohorts.

Grey-haired man in a white linen shirt pulls a grey carry-on along a palm-lined seaside promenade

What is visceral fat, and how is it different from the fat you can pinch?

Visceral fat sits inside the abdominal wall, wrapped around the liver, the gut and the other organs. The fat you can pinch is subcutaneous fat, the layer just under the skin. Two people with the same weight and the same waist can carry very different amounts of each, which is why the scale says little about the deep kind4.

The two layers behave differently. In 3,001 adults of the Framingham Heart Study scanned by CT, both were tied to blood pressure, blood sugar and blood fats, but visceral fat more strongly: each step up of one standard deviation in visceral fat came with 4.7 times the odds of metabolic syndrome in women and 4.2 times in men, against 3.0 and 2.5 for subcutaneous fat. Only visceral fat still explained risk after BMI and waist were accounted for1.

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

PepVault's Body page logs your waist in inches or centimetres beside your weight, and shows the change since your first entry.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Why does visceral fat matter for health?

These are links found by following people, not proof that the fat causes the disease. In 3,086 Framingham adults followed for a median of five years, each standard deviation more visceral fat was tied to a 44% higher risk of cardiovascular disease and a 43% higher risk of cancer, after BMI and the usual risk factors were taken into account. It was not tied to deaths from all causes over that time2.

Losing it looks like it lasts. Two Israeli diet-and-exercise trials (CENTRAL and DIRECT-PLUS) followed 366 of their volunteers 5 and 10 years later, with new MRI scans. The weight came back in full on average, yet part of the visceral fat loss held, and each 10% of visceral fat lost during the trials went with a 28% lower risk of developing type 2 diabetes afterwards3. The International Atherosclerosis Society's position statement calls visceral fat, measured by CT or MRI, an independent risk marker for cardiovascular and metabolic disease and death4.

How is visceral fat measured?

CT and MRI are the reference methods: they show the deep fat directly as an area on one slice (cm²) or a volume4. A DEXA scan, the low-dose X-ray body composition scan, also estimates it: against CT in 124 adults, the DEXA estimate explained about 96% of the variation in visceral fat volume5. At home, the tape measure is the tool, and an international panel recommends treating waist circumference as a vital sign alongside BMI6.

Who sets itGroupMenWomen
US National Institutes of Health8Adults in the USover 40 in (102 cm)over 35 in (88 cm)
International Diabetes Federation7Europid origin94 cm (37 in) or more80 cm (31.5 in) or more
International Diabetes Federation7South Asian, Chinese, Japanese90 cm (35.4 in) or more80 cm (31.5 in) or more
IAS/ICCR panel6White adults with a normal BMI90 cm or more80 cm or more
IAS/ICCR panel6White adults with a BMI of 30-34.9110 cm or more105 cm or more

The panel's point is that one cut-off for everyone misses people: a waist of 90 cm in a man of normal weight already marks higher coronary risk, while the same risk in a man with a BMI of 35 or more starts at 125 cm6. The IDF values are the ones it set for its metabolic syndrome definition, and it expects US clinics to keep using 102 and 88 cm7.

How do you measure your waist the right way?

  1. Stand up straight with your belly relaxed, with your shirt lifted so the tape sits on skin.
  2. Find the top of your hip bones with your fingers. The NIH puts the tape just above them; the WHO method uses the point halfway between the lowest rib and the hip bone. Pick one and keep it, because in women the two differ by about 2 cm68.
  3. Wrap the tape around your middle so it lies level all the way round, snug but not pressing into the skin.
  4. Breathe out normally and read the tape at the end of the breath8.
  5. Measure at the same time of day, ideally in the morning before eating, and compare each reading with your last one rather than with a single day.

PepVault's Body page logs your waist in inches or centimetres beside your weight, and shows the change since your first entry. Track your weight in PepVault

Your weigh-ins sit on the same page, so you can see the tape and the scale move side by side. Track your weight in PepVault

When to get help If your waist sits above the cut-off for your group, or keeps rising, ask your doctor to check your blood pressure, blood sugar (HbA1c) and cholesterol.

What lowers visceral fat the most?

Every row below measured visceral fat itself, not just weight. Most exercise trials used CT or MRI; the drug trials used DEXA in a subgroup of a larger trial. The trials enrolled different people for different lengths of time and never went head to head, so read each row on its own.

What was testedTrialChange in visceral fat
Aerobic exerciseMeta-analysis, 35 trials, CT or MRI9Effect size −0.33 vs no exercise; more than 30 cm² in women and 40 cm² in men, even within 12 weeks, in a second analysis10
Resistance training aloneSame meta-analysis9No significant change (effect size +0.09)
High-intensity interval training (HIIT)Network meta-analysis, 34 trials11Effect size −0.39, the largest of the exercise types
Exercise with no weight lossMeta-analysis, 117 studies, 4,815 people14−6.1% with exercise vs −1.1% with diet alone
Diet plus exercise, 18 monthsCENTRAL, 278 adults, MRI15−22% across the groups
Semaglutide 2.4 mg weeklySTEP 1 DEXA substudy, 140 adults, 68 weeks16−27.4% from baseline; little change on placebo
Tirzepatide 5-15 mg weeklySURMOUNT-1 DEXA substudy, 160 adults, 72 weeks18−40.1% vs −7.3% on placebo
Tesamorelin 2 mg dailyTwo pooled phase 3 trials, 806 adults with HIV, 26 weeks19−24 cm² vs +2 cm² on placebo (net −15.4%)

The winner on the numbers is tirzepatide: the largest measured cut, with visceral fat falling by nearly twice the percentage of body weight (−40.1% against −21.3%)18. Semaglutide showed the same pattern, −27.4% visceral fat against −15.0% body weight16. Without a drug, the trials name aerobic exercise of at least moderate intensity and HIIT as the methods that work, and resistance training alone as the weakest1112. Tesamorelin is the one drug FDA-approved to reduce excess abdominal fat, in adults with HIV and lipodystrophy21; our tesamorelin guide covers its trials.

Which exercise burns the most visceral fat: cardio, weights or HIIT?

Cardio and HIIT, roughly tied. An effect size here is a standardized difference: 0.2 is small, 0.5 medium. In the 2021 network meta-analysis of 34 trials, HIIT (−0.39) and aerobic exercise of at least moderate intensity (−0.26) lowered visceral fat, while resistance training, combined training and short all-out sprint intervals did not reach significance11. A 2024 analysis of 84 trials with 4,836 people found that all four types lowered visceral fat, ranked vigorous aerobic exercise and HIIT the most likely best, and resistance training the least effective; weights helped men and people under 40% body fat, but not women in that analysis12.

HIIT does not beat steady cardio head to head: across 11 trials scanned by DEXA, neither was better for visceral fat13. The dose that worked was modest. Three sessions a week for 12 to 16 weeks did it, with aerobic sessions of 30 to 60 minutes or HIIT sessions of under 30 or 30 to 60 minutes, and going above 150 minutes a week added no extra visceral loss11. Weights still have their own job, keeping muscle while you lose weight, which our guide on muscle on a GLP-1 covers.

Does dieting alone lower visceral fat?

Yes, in proportion to the weight you lose. Across 117 studies, both diet and exercise cut visceral fat. Diet took off more weight, but exercise trended toward the larger visceral drop, and with no weight lost at all, exercise still lowered visceral fat by 6.1% while diet alone barely moved it (1.1%)14. The scale undersells exercise for this reason.

In the 18-month CENTRAL trial, 278 adults on a low-fat or a Mediterranean low-carb diet lost 22% of their visceral fat on average by MRI. Those who also exercised lost more, about 7 cm² beyond what their weight loss explained, and the Mediterranean low-carb diet cleared more liver fat than the low-fat one15.

How much visceral fat do semaglutide and tirzepatide remove?

In STEP 1's DEXA substudy, semaglutide 2.4 mg weekly lowered regional visceral fat by 27.4% over 68 weeks, while placebo showed no major change; the trial registry puts it at −0.4 kg against −0.1 kg1617. In SURMOUNT-1's substudy, tirzepatide lowered visceral fat by 40.1% against 7.3% on placebo over 72 weeks, and the waist by 18.1 cm against 3.4 cm18. Both were exploratory analyses of small subgroups, funded and partly written by the makers.

Retatrutide's phase 2 body composition substudy in type 2 diabetes reported total fat mass, down 26.1% at 8 mg over 36 weeks, and its published abstract gives no visceral number20. Starting any of these drugs, tesamorelin included, is a prescriber's decision. What happens after you stop is the subject of our guide on stopping a GLP-1.

Commonly reported: people on a GLP-1 or a new training block say the tape and the belt notch move before the scale does, and that the belly is the first place clothes fit differently.

Track it in the app

Sources

  1. Fox CS et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation. 2007. PubMed 17576866
  2. Britton KA et al. Body fat distribution, incident cardiovascular disease, cancer, and all-cause mortality. J Am Coll Cardiol. 2013. PubMed 23850922
  3. Klein H et al. Lifestyle-induced visceral fat loss as a key target for durable cardiometabolic health: MRI-assessed 5- and 10-year follow-up after 2 clinical trials. Circulation. 2026. PubMed 42227111
  4. Neeland IJ et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol. 2019. PubMed 31301983
  5. Kaul S et al. Dual-energy X-ray absorptiometry for quantification of visceral fat. Obesity (Silver Spring). 2012. PubMed 22282048
  6. Ross R et al. Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. Nat Rev Endocrinol. 2020. PubMed 32020062
  7. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome, Table 2: ethnic specific values for waist circumference. 2006. idf.org
  8. National Heart, Lung, and Blood Institute. Assessing your weight and health risk: waist circumference. nhlbi.nih.gov
  9. Ismail I et al. A systematic review and meta-analysis of the effect of aerobic vs. resistance exercise training on visceral fat. Obes Rev. 2012. PubMed 21951360
  10. Vissers D et al. The effect of exercise on visceral adipose tissue in overweight adults: a systematic review and meta-analysis. PLoS One. 2013. PubMed 23409182
  11. Chang YH et al. Effect of exercise intervention dosage on reducing visceral adipose tissue: a systematic review and network meta-analysis of randomized controlled trials. Int J Obes. 2021. PubMed 33558643
  12. Chen X et al. Effects of various exercise types on visceral adipose tissue in individuals with overweight and obesity: a systematic review and network meta-analysis of 84 randomized controlled trials. Obes Rev. 2024. PubMed 38031812
  13. Kramer AM et al. High-intensity interval training is not superior to continuous aerobic training in reducing body fat: a systematic review and meta-analysis of randomized clinical trials. J Exerc Sci Fit. 2023. PubMed 37927356
  14. Verheggen RJ et al. A systematic review and meta-analysis on the effects of exercise training versus hypocaloric diet: distinct effects on body weight and visceral adipose tissue. Obes Rev. 2016. PubMed 27213481
  15. Gepner Y et al. Effect of distinct lifestyle interventions on mobilization of fat storage pools: CENTRAL magnetic resonance imaging randomized controlled trial. Circulation. 2018. PubMed 29142011
  16. Wilding JPH et al. Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of the STEP 1 study. J Endocr Soc. 2021 (ENDO 2021 abstract). pmc.ncbi.nlm.nih.gov
  17. ClinicalTrials.gov NCT03548935. STEP 1: semaglutide in people with overweight or obesity, posted results (body composition, DEXA analysis set). Novo Nordisk. clinicaltrials.gov
  18. Look M et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025. PubMed 39996356
  19. Falutz J et al. Effects of tesamorelin (TH9507) in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010. PubMed 20554713
  20. Coskun T et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol. 2025. PubMed 40609566
  21. EGRIFTA WR (tesamorelin) for injection, prescribing information, section 1: indications and usage. Theratechnologies. DailyMed, SPL version 2, published Aug 3, 2026. dailymed.nlm.nih.gov

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo